API Chemical Modification
Industry estimates indicate that over 80% of new chemical entities exhibit low
solubility, low bioavailability, and/or low or inconsistent dissolution rates.
Effectively addressing these drug solubility, bioavailability, and dissolution rate
issues is critical to advancing compound development and providing patients
with the therapeutic benefits needed for pharmaceutical products. The
Enhanced Bioavailability services provided by CD Formulation make us a
leader in addressing issues of low solubility, low bioavailability and dissolution
rates. Our end-to-end enhancement solutions combine the full capability to
take a compound from concept to commercialization, minimizing project
complexity, timelines and risk.
Fig.1 API Chemical Modification
Our Services
We help our clients with the ultimate manufacturability of their drug products
to avoid time-consuming reformulations and ensure fast time-to-market,
offering the following services:
